Filters
In the frontline treatment of patients with HER2-expressing locally advanced or metastatic urothelial cancer, the combination of disitamab vedotin plus toripalimab yields a clinically meaningful and significant increase in survival compared with chemotherapy, as shown in the phase III RC48-C016 trial.
Lowering the systolic blood pressure (SBP) target to <120 mm Hg compared with <140 mm Hg has a beneficial effect on retinal microvasculature among hypertensive patients with high cardiovascular risk, suggests a recent study.
People with increased sun exposure during their adolescence and early adulthood appear to have a lower risk of breast cancer, as suggested in a population-based case-control study from Iran.
In patients with type 2 diabetes (T2D), use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) is associated with a 36 percent reduction in risk of atherothrombotic major adverse cardiovascular events (MACE) vs dipeptidyl peptidase-4 inhibitors (DPP4i), a recent real-world territory-wide study in Hong Kong has shown.
In the treatment of patients with developmental and epileptic encephalopathies (DEEs), the selective serotonin 5-HT2C receptor agonist bexicaserin is well tolerated and appears to reduce the frequency of countable motor seizures, according to a phase Ib/IIa study.
Individuals with SARS‐CoV‐2 infection, especially those who are hospitalized, face long‐term declines in left ventricular ejection fraction (LVEF), according to a retrospective study.
In patients with Parkinson’s disease (PD), the high risk of mild cognitive impairment (MCI) at the time of diagnosis correlates with low levels of plasma triglycerides (P-TG) and an interaction between change in BMI and P-TG prior to diagnosis, reports a study.
Older adults with frailty are predisposed to atrial fibrillation (AF)-related hospitalizations, regardless of the presence of multimorbidity, according to a study.
Individuals exposed to brighter lights at night have increased risks of incident coronary artery disease, myocardial infarction, heart failure, atrial fibrillation, and stroke, according to a study.
For patients who are struggling to lose weight after metabolic bariatric surgery, treatment with liraglutide boosts weight-loss outcomes and helps avoid conversion surgery, as shown in a randomized clinical trial.
